Dempas (riociguat) - New Contraindication For Patients With Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (ph-iip)

ADEMPAS (riociguat), a medication used to treat pulmonary hypertension, is being recalled in Canada because it should not be used in patients with a specific type of pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) due to safety concerns. The product is being recalled across Canada. Patients currently taking ADEMPAS should consult their healthcare provider about whether this medication is appropriate for their condition.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2016-08-15

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/811ff006-c1e4-48ca-96a9-8a89a02a7501